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patients expire. METHODS: Retrospective chart review of 105
home hospice patients with a narcotic waste destruction record
who expired during a 3-month period in 2007 while receiving
care from 4 small hospices (average daily census [ADC] <60) and
1 large (ADC = 160) hospice in the Southeastern Pennsylvania
region. Data were collected through review of narcotic waste
destruction records as recorded by nurses at the time of patient
death. Strength of formulation was recorded sporadically.
Hospice nurses were surveyed about CS disposal methods.
RESULTS: Mean age of the patients was 78, (range 44–103);
majority (57%) was diagnosed with cancer, followed by heart
failure (24%). Average length of stay in hospice was 42 days
(median 21). Almost all patients had unused CS; morphine con-
centrate (20 mg/ml) was the most common medication (average
31.8 ml./patient). Collectively, over 3 liters (64,680 mg) of mor-
phine were destroyed. Lorazepam was the next most common
drug with 990 tablets and 397 ml liquid wasted. Other CS
remaining at the time of death included varying strengths of
long-acting morphine (251 tablets); OxyContin (90 tablets); and
unused transdermal fentanyl (57 patches). Hospice nurses dis-
posed of all unused CS by ﬂushing them down the toilet. CON-
CLUSION: Although not excessive on an individual level, the
amount of CS waste in hospice is signiﬁcant when viewed in the
aggregate. When ﬂushed, these medications reach water ways,
potentially posing environmental or health hazards. Regulatory
changes are required to address disposal of unused CS. Future
analyses should examine the cost of CS medication waste in
hospice.
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OBJECTIVE: The estimation of budget impact is important in
listing a new drug, but there are a lot of uncertainties. We
analyzed usage of new drug after reimbursement and investigated
various factors inﬂuencing budget impacts of the new drug to get
a guidance for public insurance BIA in Korea. METHODS: We
used 3 year claims data of 23 new drugs listed in 2004 to analyze
usage pattern and market share. We evaluated inﬂuencing factors
that clinical improvements, treatment cost, disease burden,
patient number, market competition, type of company, etc. and
conducted multiple regression analysis using these factors.
RESULTS: The indications of the 23 listing drugs were for
cancer, hypercholesterolemia, diabetes, schizophrenia, pneumo-
nia, peptic ulcer, rheumatoid arthritis, hepatitis B, HIV treat-
ment, etc. At third year after new drug listing, average market
share incrementally rose to 20% (0.06–78%, range) both in
patient number and volume of use. In case of the new drug with
clinical improve and higher cost, the average market share
amounted to 33% (n = 4). The market share of drugs with no
improve and lower costs amounted to 26% (n = 8). When total
patient number of new and pre-listed drugs were under 50,000,
market share of new drugs amounted to 25%, 35% of total
volume and patient number, respectively. But in case of over
250,000 of patients, market share of new drugs were less than
10% in both. New drugs commanded 27%, 4%, 0.08% of
market when number of pre-listed competing drugs were <25,
5–25, 25<, respectively. When the company is domestic, new
drugs amounted to about 4% of market share and 25% when it
is not. CONCLUSION: Clinical improvements, disease burden,
number of patients, number of pre-listed drug, and company type
may affect to market diffusion of new drugs. So we suggest these
results be considered in forecasting future usage of new drug and
conducting budget impact analysis.
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OBJECTIVE: The U.S. intellectual property regulations allow for
claiming the right of priority by an inventor by ﬁling a patent in
a foreign country or by ﬁling a U.S. provisional patent. The study
evaluated the provisional patent system introduced in 1994 by
the Uruguay Round Agreement Act (URAA). METHODS: Data
on patents listed in the FDA Orange Book (OB) for new chemical
entities approved between 1980 and 2007 were derived from the
USPTO. Descriptive statistics were calculated for the variables
included in the study. Chi-square and t-tests were used to assess
differences between groups. RESULTS: The OB listed 1452
patents, of which 9.6% claimed priority from a U.S. provisional
patent and 39.5% claimed priority from a foreign priority ﬁling.
The mean time gained was 328.9  75.2 days from provisional
patents and 340.8  60.3 days from foreign rights of priority.
The proportion of U.S. companies that obtained a foreign or
provisional right of priority increased from 27.4% prior to 1995
to 75.2% after 1995 (p < 0.001). This increase was due to the use
of provisional patents. A signiﬁcant increase in the use of provi-
sional patents and a signiﬁcant decrease in the use of foreign right
of priority also occurred in non-US companies, nevertheless, no
increase in the combined use of a foreign and provisional right of
priority was found for non-US companies. CONCLUSION: The
foreign companies signiﬁcantly decreased the use of foreign pri-
ority patents while increasing the use of provisional patents. The
introduction of provisional patents to the existing foreign prior-
ity system resulted in a three-fold increase in the use of these
systems by U.S. companies. The 1995 URAA change in the
USPTO priority system has signiﬁcantly inﬂuenced the frequency
by which U.S. companies seek a foreign or a provisional right of
priority.
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OBJECTIVE: The British Parliament recently held an inquiry
into the National Institute for Health and Clinical Excellence
(NICE) health technology appraisal (HTA) process. We summa-
rized stakeholder concerns about health economic and decision
methodology used for HTAs appraisals and funding decisions,
particularly with regard to serious/life-threatening illnesses,
and drew comparisons to standards among other nations that
use HTA to understand why criticisms might have arisen.
METHODS: A systematic review was conducted of written evi-
dence submitted to Parliament about the appraisal process and
corresponding health economic methods. Stakeholders were
limited to manufacturers, professional and trade associations,
and patient/disease advocacy organizations (limited to oncol-
ogy). We excluded evidence from individuals. We extracted
themes from this evidence and generated items for a comparison
of methods of other countries that conduct appraisals. Only
publicly available, English-language qualitative data were con-
sidered. RESULTS: We identiﬁed written evidence from 92
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constituents through August 1, 2007, of which evidence from 27
were extracted using our criteria. Stakeholder comments on the
HTA process and decision methodology were distilled into 12
categories, ranging from impact of severity/rarity of disease on
acceptability of cost-effectiveness thresholds to over-reliance of
QALYs in decision-making. Compared to attributes reported for
other countries, NICE’s criteria and methods for health eco-
nomic assessment and decision-making varied substantially, such
as that of the model perspective, e.g., payer versus societal.
CONCLUSION: We found that aspects of NICE technology
appraisals garner criticism common to many stakeholders. This
underscores the need to reconsider how current health economic
and decision methodology might be improved. Furthermore,
country-level heterogeneity in HTA processes and methods sug-
gests the need to determine why these variations arise, and
whether they reﬂect societal preferences or misunderstandings of
appropriate methods.
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OBJECTIVE: Political objectives may alter economic rationale in
health care decision-making. The Hungarian government had
promised to reduce the prices and copayment of pharmaceuti-
cals, therefore 15% price cut was mandated to all reimbursed
pharmaceuticals from April 2004. Three months later the regu-
lation was abrogated by the Constitution Court. As the govern-
ment did not want to communicate a price increase, the level of
copayment remained the same, while the reimbursement level
was increased. It took two years to increase the copayment back
to the original level by a 7.5% reimbursement reduction in
February 2005, and by a further 7.5% reduction from February
2005 to July 2006. Our objective was to measure the impact of
price cut on the public pharmaceutical budget. METHODS: An
estimated public pharmaceutical spending was calculated based
upon projections from the expenditure in previous periods.
Only pharmaceuticals with reimbursement in April 2004 were
included into the analysis. The estimated expenditure was com-
pared to the real expenditure. Hungarian Forint was converted to
US$ by employing the quarterly exchange rate. RESULTS: In Q2
2004 the mandated price cut resulted in $39.65 million savings in
the pharmaceutical expenditure. In Q3-Q4 2004 the reduced
copayment generated $29.98 million increase in the drug budget.
Between Q1 2005 and Q2 2006 the impact of reduced copay-
ment was $42.42 million. CONCLUSION: The mandated price
cut and its subsequent abrogation resulted in $32.75 million
increase in the Hungarian public pharmaceutical expediture
between April 2004 and June 2006, as the government did not
dare to withdraw its promise on cheaper pharmaceuticals. Our
estimate is conservative, as the mandated price cut inﬂuenced
spending not only on pharmaceuticals with reimbursement in
April 2004, but via reference pricing also the spending on new
pharmaceuticals with initial reimbursement between April 2004
and June 2006.
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OBJECTIVE: To estimate the effect of prescription drug insur-
ance on health, as measured by self-reported poor health status,
functional disability, and hospitalization among elderly with at
least three chronic conditions. METHODS: Analyses are based
on a nationally representative sample of non-institutionalized
elderly (>64 years of age) from the Medicare Current Beneﬁ-
ciary Survey (MCBS) for years 1992–2000. Estimates are
obtained using multivariable regression models that control for
observed characteristics and unmeasured person-speciﬁc effects
(i.e., ﬁxed effects). Fixed effects analysis uses within person
variation in drug coverage to estimate the effect of gaining or
losing coverage on outcome of interest (i.e., health). RESULTS:
In general, prescription drug insurance was not associated with
signiﬁcant changes in self-reported health, and hospitalization.
However, prescription drug coverage decreased functional dis-
ability slightly (4% improvement), although this was not sta-
tistically signiﬁcant. CONCLUSION: Findings suggest that
prescription drug coverage may have some health beneﬁts for
chronically ill.
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OBJECTIVE: During the 16 months preceding the start of the
Medicare prescription drug program (Part D), 22,359 vulnerable
Medicare beneﬁciaries with rheumatoid arthritis (RA) or mul-
tiple sclerosis (MS) participated in the Medicare Replacement
Drug Demonstration (MRDD), which provided access to spe-
cialty biologic medications. We examine beneﬁciary characteris-
tics associated with Part D enrollment among this population in
early 2006. METHODS: Predictors in multivariate logistic
regressions included female gender, age, race (white, black, or
other), region of the U.S., urban residence, Hierarchical Condi-
tion Category score (HCC; a measure of comorbidity), use of the
MRDD beneﬁt, subsidy level under the MRDD, self-report of
other drug coverage during the MRDD, and death within six
months of the start of Part D. RESULTS: Among 14,963 MRDD
beneﬁciaries with RA, 12,174 (81%) enrolled in Part D plans
during the ﬁrst half of 2006. Ninety percent (6646) of the 7396
beneﬁciaries with MS enrolled in a Part D plan—about 50%
higher than the rate of enrollment in the general Medicare popu-
lation. Female gender (OR = 1.5, 1.3–1.6), MRDD beneﬁt use
(OR = 2.6, 2.4–2.8), higher HCC score (OR = 1.07, 1.03–1.10),
other drug coverage during the MRDD (OR = 1.6, 1.5–1.7),
were associated with Part D enrollment. There were regional
differences as well. Older age (OR = 0.9, 0.9–0.9) and death
within 6 months (OR = 0.3, 0.3–0.4) were associated with not
enrolling in Part D. Separate regressions for the RA and MS
populations produced similar results. CONCLUSION: With the
inception of Medicare Part D, most MRDD beneﬁciaries with
RA and MS enrolled in Part D plans. Beneﬁciaries who had used
their MRDD beneﬁt and had worse health status—those who
appear to need prescription drug coverage most—were more
likely to enroll. Disproportionately high enrollment suggests that
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